Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
BeOne Medicines
AstraZeneca
BeOne Medicines
BeOne Medicines
Thomas Jefferson University
National Cancer Institute (NCI)
AVM Biotechnology Inc
BeOne Medicines
BeOne Medicines
BeOne Medicines
Nantes University Hospital
Ohio State University Comprehensive Cancer Center
BeOne Medicines
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc.
Ohio State University Comprehensive Cancer Center
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Wake Forest University Health Sciences
National Cancer Institute (NCI)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Massachusetts General Hospital
Genmab
Janssen Research & Development, LLC
Grifols Therapeutics LLC
Janssen Research & Development, LLC
AbbVie
Merck Sharp & Dohme LLC
Janssen Cilag S.A.S.
AstraZeneca
Janssen Research & Development, LLC
National Cancer Institute (NCI)
The Royal Wolverhampton Hospitals NHS Trust
Nurix Therapeutics, Inc.
UNC Lineberger Comprehensive Cancer Center
University of Utah
Mayo Clinic
AbbVie
National Institutes of Health Clinical Center (CC)
Genmab
Calibr, a division of Scripps Research